Skip to main content
Home
About
Company Overview
Team
Partners
Careers
Patient Resource
Pipeline
Investors
Newsroom
Contact
Facebook
Twitter
Linkedin
MENU
Home
About
Company Overview
Team
Partners
Careers
Patient Resource
Pipeline
Investors
Newsroom
Contact
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Press Releases
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2019
2018
2017
2016
12/04/2019
Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma
12/02/2019
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Mexico With Alternavida S.A.
11/26/2019
Tetra Bio-Pharma Confirms Submission of Two OTC DIN Applications to Health Canada
11/25/2019
FDA Approves Advancement of PPP001 Clinical Trial Previously Discontinued
11/18/2019
Tetra Bio-Pharma Secures Financing for Hemp Energy Drink Business
11/13/2019
Tetra Bio-Pharma Joins BIOTECanada
11/11/2019
Tetra Bio-Pharma Confirms Regulatory Strategy of Lead Product CAUMZ™ and Strengthens Management Team
10/30/2019
Tetra Bio-Pharma Provides Management Update on Tetra Natural Health’s Commercial Activities
10/21/2019
Tetra Bio-Pharma Provides Management Update on Commercializing its Inhalation Drug Caumz®
10/03/2019
Tetra Bio-Pharma Provides Regulatory Update for Its CAUMZ(TM) Kit
08/21/2019
Tetra Bio-Pharma Announces Joint Venture with Thorne and Onegevity Health to Form CB2 Therapeutics
08/12/2019
Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci Public Relations as Strategic Partners
08/02/2019
Tetra's Officers and Employees Participate in Private Placement
07/30/2019
Tetra's Officers and Employees Participate in Private Placement
07/18/2019
Tetra Bio-Pharma’s Management Post Financing Corporate Update
Download
PDF format download (opens in new window)
07/12/2019
Tetra Bio-Pharma Announces Closing of Unit Offering
07/11/2019
Panag Pharma Receives a Repayable $500,000 Contribution from the Atlantic Canada Opportunities Agency (ACOA)
07/05/2019
Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
06/24/2019
Tetra Bio-Pharma Inc. Announces Pricing of Unit Offering
06/21/2019
Tetra Bio-Pharma Inc. Announces Voting Results of 2019 Annual General and Special Meeting
06/19/2019
Tetra Bio-Pharma Inc. Announces Proposed Offering of Units
06/18/2019
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
06/17/2019
Tetra Bio-Pharma Inc. Announces Change of Annual General Meeting Time
06/17/2019
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
06/14/2019
Tetra Bio-Pharma Inc. Announces Director Resignation
06/11/2019
Panag Pharma Completes Phase 3 Trial With Awaye™
05/30/2019
Tetra Bio-Pharma to Present Key Research Findings as Part of Food and Drug Administration (FDA) Public Hearing on CBD
05/14/2019
Tetra Bio-Pharma Announces the Retirement of Bernard Lessard and the Appointment of Sabino Di Paola as Chief Financial Officer
05/09/2019
Tetra Bio-Pharma’s Recently acquired Wholly Owned Subsidiary Panag Pharma Provides an Update on Recent Activities
05/02/2019
Tetra Bio-Pharma’s Subsidiary, Panag Pharma, Obtains Health Canada Authorization to Commence Its First Veterinary Clinical Study
05/01/2019
Tetra Bio-Pharma Closes the Acquisition of Panag Pharma
04/29/2019
Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development
04/18/2019
Tetra Bio-Pharma Shareholders Approve the Acquisition of Panag Pharma
04/11/2019
Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer
04/09/2019
Tetra Bio-Pharma Resumes its Phase 3 Clinical Trial Program
04/01/2019
Tetra Bio-Pharma Announces Employment Contract Renewal of CEO Guy Chamberland
03/27/2019
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
03/06/2019
Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team
03/04/2019
Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients
02/26/2019
Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance
02/12/2019
Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program
02/08/2019
Tetra Bio-Pharma Announces Stock Option Grants
02/07/2019
Tetra Bio-Pharma Pursues Its Research Priorities Accelerating Other Drug Development Plans
02/05/2019
Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
02/04/2019
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio
01/30/2019
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Download
PDF format download (opens in new window)
01/28/2019
Tetra Bio-Pharma Files Patent Application to Protect PPP001
01/14/2019
Tetra Natural Health Adds New Leaders to its Commercial Operations